DNA EXTRACTION KITS MARKET ANALYSIS

Market Size and Trends

The DNA extraction kits market is estimated to be valued at USD 1,622.1 Mn in 2024 and is expected to reach USD 2,792.5 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.1% from 2024 to 2031.

To learn more about this report, request a free sample copy

The DNA extraction kits market is expected to witness positive growth over the forecast period. DNA extraction kits are essential for researchers performing clinical and forensic analyses that require the isolation of nucleic acids. The rising focus on personalized medicine and precision diagnostics will drive the demand for DNA extraction kits over the coming years. The DNA extraction kits market is expected to witness significant growth over the forecast period. This can be attributed to factors such as increasing application of genomic & proteomic studies, rising number of legal cases requiring DNA extraction, and growing demand for the customizable DNA extraction platform. Additionally, growing investments by governments and private organizations to promote genomics R&D is also fueling the market growth. However, high costs associated with DNA extraction procedures and the requirement of skilled professionals may hamper the market expansion.

Increasing Research and Development Activities in Genomics

Advancements in the field of genomics over the past century, have led to substantial reductions in the cost of genome sequencing and increase in spending on R&D activities. Biobanks help to know how genetic elements are associated with disorder consequences. For instance, in September 2022, Sun Yat-sen University, China, a national public research university, initiated a clinical trial titled ‘Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for Surveillance.’ The study is estimated to get competed by January 31, 2027. Moreover, in October 2020, Rigshospitalet, a multispecialty hospital, initiated a clinical trial titled ‘Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer.’ The study is estimated to get completed by July 2025.

Market Concentration and Competitive Landscape

To learn more about this report, request a free sample copy

About 80% of rare diseases are genetic in origin. Therefore, genome sequencing-based diagnosis offers a promising alternative for rare-disease management. The number of rare diseases is around 7,000, and most of them are usually chronically debilitating or even life-threatening. Genomics is driving a fundamental shift in rare disease diagnosis, from symptom analysis to molecular etiology assessment, and hence will drive the demand for DNA extraction kits. Increase in the prevalence of genetic disorders is expected to drive the growth of the global DNA extraction kits market over the forecast period. For instance, according to data published on February 27, 2023, by the World Health Organization, it was estimated that 240,000 newborns die worldwide within 28 days of birth every year due to genetic disorders. Genetic disorders further results in 170,000 deaths globally of children between the ages of 1 month and 5 years every year.

To learn more about this report, request a free sample copy

Technologically advanced DNA extraction kits are costlier than conventional methods. DNA extraction for a single sample or numerous samples of different sizes using different kits can be expensive. Furthermore, hazardous reagents used for more accurate and fast results can lead to impurities in results. DNA extraction is a basic process in molecular research studies and extracted DNA has many advanced downstream applications in the field of medicine. Extracted DNA is used in various applications such as Polymerase Chain Reaction (PCR), cloning, genome sequencing, and others. Using different DNA extraction kits for different applications makes the process expensive for end users in the market. The cost and time required for developing a single reagent for DNA extraction are high. Furthermore, DNA from various types of samples such as the human genome, plants, bacteria, forensic dried blood samples, etc., have distinct features and characteristics and need to be extracted or processed with the right DNA extraction methods. The cost of R&D increases, as key players are focused on developing next- generation, technologically advanced, high-yielding, and fast-processing DNA extraction kits. This, in turn, makes commercial DNA extraction kits expensive.

Market Opportunities – Availability of Next-generation DNA Extraction Kits

Increasing availability of next-generation DNA extraction kits by the key players in the market are expected to offer lucrative growth opportunities during the forecast period. DNA extraction is a common process in molecular biology laboratories. However, it is a tedious and time-consuming routine task. For instance, in May 2021, 30M Genomics, an India-based startup, developed a new technology called AmpReady, to extract DNA from biological samples without any equipment in five seconds. Moreover, in October 2020, Purigen Biosystems, Inc., a biotechnology company, announced the launch of Ionic Cells to Pure DNA Low Input Kit for researchers working with limited biological samples. The simplified and automated 60-minute workflow delivers high-quality DNA for rapid investigation of genetic abnormalities or examination of disease treatment effects.

To learn more about this report, request a free sample copy

The product segment includes cell-free DNA, genomic DNA, and others. The cell-free DNA segment is estimated to hold 46.5% share of the market in 2024 owing to the increasing utility of liquid biopsy techniques for non-invasive cancer diagnosis and monitoring. Cell-free DNA extraction kits are seeing widespread adoption from both research and clinical settings for analyzing circulating tumor DNA (ctDNA) from blood samples. Liquid biopsies provide a simple and repeatable method for capturing mutational biomarkers from tumors without invasive tissue sampling. This non-invasive approach allows for real-time monitoring of disease progression or response to therapies. The higher accuracy and sensitivity of next-generation sequencing technologies have also improved the clinical relevance of ctDNA analysis. Furthermore, cell-free DNA extraction kits offer advantages over tissue biopsies such as early detection of various cancers before anatomical changes occur. The lack of invasiveness with liquid biopsies makes them an attractive option for multiple assays during treatment without risk or pain to the patient. Growing investments in liquid biopsy research and favorable reimbursement scenarios for non-invasive diagnostic tests are fueling the sales of cell-free DNA extraction kits.

Insights, By Application: Widespread and Expanding Applications in Genomics and Precision Medicine

The application segment includes PCR, sequencing, cloning, and others. The PCR subsegment is expected to hold 36.6% of the market share in 2024 due to their widespread and expanding applications in genomics and precision medicine. DNA extraction kits designed for PCR are indispensable for a variety of basic molecular applications including gene expression analysis, mutation detection, genotyping, and microbial identification. Meanwhile, DNA extraction kits tailored for next generation sequencing see heightened demand from genomic, transcriptomic, and metagenomic research. Rapid reductions in the cost of high-throughput sequencing technologies have propelled their utility for clinical genomic applications such as non-invasive prenatal testing, cancer panel screening and personalized medicine. In precision oncology, genomic profiling of tumor biopsies via DNA sequencing helps guide treatment decisions and pinpoint targeted therapies. The advancement of single-cell sequencing techniques also drives the need for robust DNA extraction from low sample inputs. The push for large-scale genomic initiatives and growing focus on personalized healthcare based on individual genomic screening is stimulating continued product innovation and uptake of DNA extraction kits for PCR and sequencing applications.

Insights, By Sample Type: Widespread Diagnostic and Monitoring Needs Associated with Chronic Diseases

The sample type segment includes blood, tissue & FFPE, cells, and others. The blood subsegment is expected to hold 68.6% of the market share in 2024 owing to the widespread diagnostic and monitoring needs associated with chronic diseases. For instance, blood samples are routinely collected for early cancer screening and testing for genetic disorders. Tissue biopsies allow for histopathological examination and molecular profiling of tumor samples. FFPE samples stored from excised tissues remain an important archived resource for retrospective genetic analysis. The rising global prevalence of chronic illnesses such as cancer amplifies the demand for diagnostic testing aided by DNA extraction from various sample types. An aging population also translates to higher risk of comorbidities that require lifelong monitoring through biomarker analysis. Moreover, post-operative molecular analysis of resected tissue samples enables surveillance of residual disease or tumor recurrence. Technological improvements now facilitate efficient extraction of high-quality DNA even from formalin-fixed clinical samples. The drive for effective healthcare solutions and shift towards preventive care models further propel the utility of DNA-based testing from diverse sample types.

Regional Insights

To learn more about this report, request a free sample copy

North America remains the dominant region in the global DNA extraction kits market and is anticipated to hold 36.7% of the market share in 2024. North America has established itself as the dominant regional market for DNA extraction kits. This can be attributed to a well-developed healthcare infrastructure and widespread genetic testing adoption in the region. The U.S., in particular, has seen exponential growth in the direct-to-consumer genetic testing business, fueling the demand for DNA extraction kits from both established laboratories as well as new startups. Besides strong domestic demand, North America also benefits from a skilled bioscience workforce and conducive regulatory environment that encourages research and development investments by industry players. Leading kit manufacturers have their headquarters and manufacturing facilities located in the region, ensuring high product availability and support.

 Asia Pacific market has emerged as one of the fastest growing regional markets for DNA extraction kits. Counties like India, Indonesia, Vietnam, and Thailand have large and youthful populations increasingly aware about genetic screening. This consumer market potential is attracting global kit suppliers to focus on the region. Simultaneously, governments of developing economies are investing in modernizing their clinical diagnostic infrastructure. This includes setting up new genome sequencing facilities and expanding the use of genetic tests within public health programs. Such initiatives will further stimulate the uptake of DNA extraction solutions in coming years. The presence of well-established pharmaceutical companies and contract manufacturing industries has also made Asia Pacific an outsourcing and manufacturing hub for global life science firms.

Market Report Scope

Key Developments

• In March 2023, OraSure Technologies, a medical device company, and nRichDX, which provides In-vitro Diagnostic (IVD) liquid biopsy samples and molecular testing, announced a collaboration to validate and co-promote their research-use technologies to analyze cell-free DNA from urine
• In February 2023, Bionano Genomics, Inc, a biotechnology company, announced the China National Medical Products Administration (NMPA) approval for DNA Extraction Kits and Labeling Products for In vitro diagnostics (IVD) Use in hematologic malignancies
• In November 2022, RevoluGen, a biotechnology company, announced a partnership with Tecan, a biotechnology company, to transform high molecular weight DNA extraction kits. The partnership will support the manufacturing and supply of Tecan’s 96-well filter plates to be used in RevoluGen’s automated Fire Monkey high molecular weight (HMW)-DNA extraction kits.
• In May 2022, Biotium, a supplier of cutting-edge life science reagents, announced the acquisition of Cell Data Sciences RNAstorm and DNAstorm kits for RNA/DNA extraction. Biotium, which previously distributed Cell Data Sciences kits, will now be their sole manufacturer. The extraction kits will be offered from the Biotium website and authorized distributors.
• In October 2021, Thermo Fisher Scientific Inc., a medical device company, announced that it will manufacture its Applied Biosystems MagMAX Dx Prefilled Viral/Pathogen Nucleic Acid Isolation kits in India for Indian markets
• In February 2020, Promega Corporation, a global biotechnology manufacturer, launched its new Wizard HMW DNA Extraction Kit for researchers working with large fragments of genomic DNA. The kit enables researchers to obtain DNA that will provide strong performance in long-read sequencing applications in a 90-minute manual protocol. The kit supports purification from a variety of sample types including whole blood, bacterial cultures, cultured mammalian cells, and plant leaf tissue.

*Definition: The DNA extraction kits market comprises various products and tools required to isolate DNA from various biological samples such as blood, tissues, cells, etc. Extraction kits use methods like column chromatography to separate DNA from other cellular components. They provide optimized buffer formulations and separation membranes to purify DNA. The purified DNA can then be utilized in various downstream applications ranging from molecular biology research to clinical diagnostics. DNA extraction kits help researchers and healthcare professionals accurately isolate DNA for analysis in a fast, simple, and cost-effective manner.

Market Segmentation

•  Product Insights (Revenue, USD Mn, 2019 - 2031)
  • Cell-free DNA
  • Genomic DNA
  • Others
• Application Insights (Revenue, USD Mn, 2019 - 2031)
  • PCR
  • Sequencing
  • Cloning
  • Others
• Sample Type Insights (Revenue, USD Mn, 2019 - 2031)
  • Blood, tissue & FFPE
  • Cells
  • Others
•  End User Insights (Revenue, USD Mn, 2019 - 2031)
  • Healthcare Facilities
  • Pharmaceutical and Biotechnology Company
  • Research Institutes
  • Others
• Regional Insights (Revenue, USD Mn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Bio-Rad Laboratories, Inc.
  • Zymo Research Corporation
  • Promega Corporation
  • Omega Bio-tek, Inc.
  • Thermo Fisher Scientific Inc.
  • Minerva Biolabs GmbH
  • Merck KGaA
  • Kaneka Corporation
  • Canvax Reagents S.L.
  • Biotium
  • Genome Diagnostics Pvt. Ltd.
  • Generi Biotech
  • BioChain Institute Inc.
  • Bertin Instrument
  • Isohelix